SlideShare a Scribd company logo
The Fetal Medicine
Foundation
Sofía Fournier
Margarita Torrents
Cayetana Barbed
Mónica Echevarría
Mina Comas
MARBELLA, JUNE 2013
SELECTIVE EMBRYO-FETAL REDUCTION.
OUR EXPERIENCE OVER THE LAST 20 YEARS
FACTORS AFFECTING OUTCOME
HOSPITAL UNIVERSITARIO QUIRÓN DEXEUS, BARCELONA. SPAIN
0%
10%
20%
30%
40%
50%
60%
<37
weeks
< 34
weeks
< 32
weeks
congenital defect
multiple pregnancy
N: 177
From 1989 to 2011
The Fetal Medicine
Foundation
Selective embryo-fetal reduction.
Factors affecting outcome
Objective:
To analyze our own results in selective embryo-fetal reductions during a 22-year
period, focusing on percentage of fetal loss and prematurity rate
Material and methods:
177 embryo-fetal reductions performed from 1989 to
2011
149 cases with a complete follow-up (84,2%)
Indications:
64,9% multiple pregnancy
35,02% congenital defect
Only one operator performing all the cases
Introduction:
Indications for a selective embryo-fetal reduction in our hospital:
-High order multiple pregnancies (>3) or triplets in high-risk patients
-Congenital defect in one of the embryos/fetuses
The Fetal Medicine
Foundation
Results: Fetal loss according to:
Selective embryo-fetal reduction.
Factors affecting outcome
P: 0,59 P: 0,77
P: 0,23
 No significant relationship with
GA.
 Higher risk <10th week: linked
to cases performed during the
initial period (higher number of
embryos to reduce and less
experience).
 Trend higher risk >12th week
 No significant relationship with
the initial number of fetuses (trend
to increased risk when > 3 fetuses)
 No significant relationship with
the number of fetuses reduced
(trend to increased risk when >1
fetus)
GA procedure Initial n fetuses n fetuses reduced
The Fetal Medicine
Foundation
Results:
Selective embryo-fetal reduction.
Factors affecting outcome
INDICATION OVERALL
CONGENITAL
DEFECT
MULTIPLE
PREGNANCY
NOT COMPLETE
INFORMATION
13
21%
15
13%
28
15,8%
FETAL LOSS
5
8,1%
12
10,4%
17
9,6%
< 37 WEEKS
9
14,5%
49
42,6%
58
32,8%
>37 WEEKS
35
56,5%
39
33,9%
74
41,8%
OVERALL
62
35,02%
115
64,9%
177
100%
Overall fetal loss rate: 9,6%
 8,1% when congenital defect
10,4% when multiple pregnancy
Overall prematurity rate: 32,8%
14,5% in the congenital defect group
42,6% in the multiple pregnancy group
P < 0,05
0%
10%
20%
30%
40%
50%
60%
multiple pregnancy
congenital defect
P>0,05
Learning curve
% fetal loss
The Fetal Medicine
Foundation
Conclusions
Thank you
Selective embryo-fetal reduction.
Factors affecting outcome
11%
 Indication for selective embryo-fetal reduction has significantly changed:
 Multiple pregnancies in high-risk patients used to be the most frequent
 Congenital defects is the most frequent indication nowadays
 The overall perinatal result is worse in cases due to multiple pregnancy,
with a higher rate of fetal loss and prematurity.
 No significant relationship with GA, initial number of fetuses nor number
of fetuses reduced
 Trend to increased risk when >12 weeks (importance of earlier diagnosis)
 Trend to increased risk when >3 initial fetuses
 Trend to increase when >1 fetus reduced
Performing the technique by expert hands with an appropriate learning curve
guarantees better perinatal results.

More Related Content

What's hot

Predictive Factors influencing pregnancy rate after intrauterine insemination
Predictive Factors influencing pregnancy rate after intrauterine inseminationPredictive Factors influencing pregnancy rate after intrauterine insemination
Predictive Factors influencing pregnancy rate after intrauterine insemination
DrRokeyaBegum
 
Single Embryo Transfer
Single Embryo TransferSingle Embryo Transfer
Single Embryo Transfer
Dr.Laxmi Agrawal Shrikhande
 
Fibroid & infertility
Fibroid & infertilityFibroid & infertility
Fibroid & infertility
Hesham Al-Inany
 
Ectopic pregnancy future fertiliy
Ectopic pregnancy future fertiliyEctopic pregnancy future fertiliy
Ectopic pregnancy future fertiliy
Poonam Loomba
 
How evidence can change practice
How evidence can change practiceHow evidence can change practice
How evidence can change practice
Hesham Al-Inany
 
Endometrioma and how it affects IVF outcome : modified procedure with encoura...
Endometrioma and how it affects IVF outcome : modified procedure with encoura...Endometrioma and how it affects IVF outcome : modified procedure with encoura...
Endometrioma and how it affects IVF outcome : modified procedure with encoura...
Mohamed Walaa El Deeb
 
Twins after IVF : revisited
Twins after IVF : revisitedTwins after IVF : revisited
Twins after IVF : revisited
Hesham Al-Inany
 
Letrozol & reproduction
Letrozol & reproductionLetrozol & reproduction
Letrozol & reproduction
Hesham Al-Inany
 
Changing the Concept of Tubal Ectopic Pregnancy
Changing the Concept of Tubal Ectopic PregnancyChanging the Concept of Tubal Ectopic Pregnancy
Changing the Concept of Tubal Ectopic Pregnancy
Mohamed Walaa El Deeb
 
Day 3 vs day 5 embryo transfer
Day 3 vs day 5 embryo transferDay 3 vs day 5 embryo transfer
Day 3 vs day 5 embryo transfer
Hesham Al-Inany
 
Surgical treatment of infertility: pre and post - Dr. Abayomi Ajayi
Surgical treatment of infertility: pre and post - Dr. Abayomi AjayiSurgical treatment of infertility: pre and post - Dr. Abayomi Ajayi
Surgical treatment of infertility: pre and post - Dr. Abayomi Ajayi
abayomi ajayi
 
GnRH costeffectiveness
GnRH costeffectivenessGnRH costeffectiveness
GnRH costeffectiveness
Hesham Al-Inany
 
Multifoetal reduction in Infertility
Multifoetal reduction in InfertilityMultifoetal reduction in Infertility
Multifoetal reduction in Infertility
Sujoy Dasgupta
 
Screening for fetal aneuploidy
Screening for fetal aneuploidyScreening for fetal aneuploidy
Screening for fetal aneuploidy
Poonam Loomba
 
Baseline scan in infertility
Baseline scan in infertilityBaseline scan in infertility
Baseline scan in infertility
Poonam Loomba
 
Final Oocyte Maturation: HCG VS GNRH Agonist by Dr. Abayomi Ajayi
Final Oocyte Maturation: HCG VS GNRH Agonist by Dr. Abayomi AjayiFinal Oocyte Maturation: HCG VS GNRH Agonist by Dr. Abayomi Ajayi
Final Oocyte Maturation: HCG VS GNRH Agonist by Dr. Abayomi Ajayi
abayomi ajayi
 
Doctor, will I be able to have a baby ? Fertility after cancer
Doctor, will I be able to have a baby ? Fertility after cancer Doctor, will I be able to have a baby ? Fertility after cancer
Doctor, will I be able to have a baby ? Fertility after cancer
Dr Aniruddha Malpani
 
The Role of laparoscopy in the era of ART
The Role of laparoscopy in the era of ARTThe Role of laparoscopy in the era of ART
The Role of laparoscopy in the era of ART
DrRokeyaBegum
 
Recurrent Implantation Failure
Recurrent Implantation FailureRecurrent Implantation Failure
Recurrent Implantation Failure
Shivani Sachdev
 
PREVENTION OF PRETERM LABOUR - EVIDENCES FOR PROGESTERONE BY DR SHASHWAT JANI
PREVENTION OF PRETERM LABOUR - EVIDENCES FOR PROGESTERONE BY DR SHASHWAT JANIPREVENTION OF PRETERM LABOUR - EVIDENCES FOR PROGESTERONE BY DR SHASHWAT JANI
PREVENTION OF PRETERM LABOUR - EVIDENCES FOR PROGESTERONE BY DR SHASHWAT JANI
DR SHASHWAT JANI
 

What's hot (20)

Predictive Factors influencing pregnancy rate after intrauterine insemination
Predictive Factors influencing pregnancy rate after intrauterine inseminationPredictive Factors influencing pregnancy rate after intrauterine insemination
Predictive Factors influencing pregnancy rate after intrauterine insemination
 
Single Embryo Transfer
Single Embryo TransferSingle Embryo Transfer
Single Embryo Transfer
 
Fibroid & infertility
Fibroid & infertilityFibroid & infertility
Fibroid & infertility
 
Ectopic pregnancy future fertiliy
Ectopic pregnancy future fertiliyEctopic pregnancy future fertiliy
Ectopic pregnancy future fertiliy
 
How evidence can change practice
How evidence can change practiceHow evidence can change practice
How evidence can change practice
 
Endometrioma and how it affects IVF outcome : modified procedure with encoura...
Endometrioma and how it affects IVF outcome : modified procedure with encoura...Endometrioma and how it affects IVF outcome : modified procedure with encoura...
Endometrioma and how it affects IVF outcome : modified procedure with encoura...
 
Twins after IVF : revisited
Twins after IVF : revisitedTwins after IVF : revisited
Twins after IVF : revisited
 
Letrozol & reproduction
Letrozol & reproductionLetrozol & reproduction
Letrozol & reproduction
 
Changing the Concept of Tubal Ectopic Pregnancy
Changing the Concept of Tubal Ectopic PregnancyChanging the Concept of Tubal Ectopic Pregnancy
Changing the Concept of Tubal Ectopic Pregnancy
 
Day 3 vs day 5 embryo transfer
Day 3 vs day 5 embryo transferDay 3 vs day 5 embryo transfer
Day 3 vs day 5 embryo transfer
 
Surgical treatment of infertility: pre and post - Dr. Abayomi Ajayi
Surgical treatment of infertility: pre and post - Dr. Abayomi AjayiSurgical treatment of infertility: pre and post - Dr. Abayomi Ajayi
Surgical treatment of infertility: pre and post - Dr. Abayomi Ajayi
 
GnRH costeffectiveness
GnRH costeffectivenessGnRH costeffectiveness
GnRH costeffectiveness
 
Multifoetal reduction in Infertility
Multifoetal reduction in InfertilityMultifoetal reduction in Infertility
Multifoetal reduction in Infertility
 
Screening for fetal aneuploidy
Screening for fetal aneuploidyScreening for fetal aneuploidy
Screening for fetal aneuploidy
 
Baseline scan in infertility
Baseline scan in infertilityBaseline scan in infertility
Baseline scan in infertility
 
Final Oocyte Maturation: HCG VS GNRH Agonist by Dr. Abayomi Ajayi
Final Oocyte Maturation: HCG VS GNRH Agonist by Dr. Abayomi AjayiFinal Oocyte Maturation: HCG VS GNRH Agonist by Dr. Abayomi Ajayi
Final Oocyte Maturation: HCG VS GNRH Agonist by Dr. Abayomi Ajayi
 
Doctor, will I be able to have a baby ? Fertility after cancer
Doctor, will I be able to have a baby ? Fertility after cancer Doctor, will I be able to have a baby ? Fertility after cancer
Doctor, will I be able to have a baby ? Fertility after cancer
 
The Role of laparoscopy in the era of ART
The Role of laparoscopy in the era of ARTThe Role of laparoscopy in the era of ART
The Role of laparoscopy in the era of ART
 
Recurrent Implantation Failure
Recurrent Implantation FailureRecurrent Implantation Failure
Recurrent Implantation Failure
 
PREVENTION OF PRETERM LABOUR - EVIDENCES FOR PROGESTERONE BY DR SHASHWAT JANI
PREVENTION OF PRETERM LABOUR - EVIDENCES FOR PROGESTERONE BY DR SHASHWAT JANIPREVENTION OF PRETERM LABOUR - EVIDENCES FOR PROGESTERONE BY DR SHASHWAT JANI
PREVENTION OF PRETERM LABOUR - EVIDENCES FOR PROGESTERONE BY DR SHASHWAT JANI
 

Similar to Selective embryo-fetal reduction

AN ANALYSIS OF OUTCOMES IN TWIN PREGNANCIES WITH ACTIVE FETAL SURVEILLANCE AN...
AN ANALYSIS OF OUTCOMES IN TWIN PREGNANCIES WITH ACTIVE FETAL SURVEILLANCE AN...AN ANALYSIS OF OUTCOMES IN TWIN PREGNANCIES WITH ACTIVE FETAL SURVEILLANCE AN...
AN ANALYSIS OF OUTCOMES IN TWIN PREGNANCIES WITH ACTIVE FETAL SURVEILLANCE AN...
Apollo Hospitals
 
I Jornada Actualización en Genética Reproductiva y Fertilidad
I Jornada Actualización en Genética Reproductiva y Fertilidad I Jornada Actualización en Genética Reproductiva y Fertilidad
I Jornada Actualización en Genética Reproductiva y Fertilidad
TECNALIA Research & Innovation
 
Preterm Labor by Yinka Oyelese
Preterm Labor by Yinka OyelesePreterm Labor by Yinka Oyelese
preterm and postterm labour
 preterm and postterm labour preterm and postterm labour
preterm and postterm labour
Zeeshan Khan
 
Unexplained Infertility 2009 (Assisted Reproductive Technologies)
Unexplained Infertility 2009 (Assisted Reproductive Technologies)Unexplained Infertility 2009 (Assisted Reproductive Technologies)
Unexplained Infertility 2009 (Assisted Reproductive Technologies)
Anu Test Tube Baby Centre
 
O&G PRETERM DELIVERY, Tutorial for 2024 v1
O&G PRETERM DELIVERY, Tutorial for 2024 v1O&G PRETERM DELIVERY, Tutorial for 2024 v1
O&G PRETERM DELIVERY, Tutorial for 2024 v1
getplaye
 
Universal screening for gestational diabetes by DIPSI test by Dr.Preksha
Universal screening for gestational diabetes by DIPSI test by Dr.PrekshaUniversal screening for gestational diabetes by DIPSI test by Dr.Preksha
Universal screening for gestational diabetes by DIPSI test by Dr.Preksha
Dr. Preksha Jain
 
Preterm labor
Preterm laborPreterm labor
Preterm labor
Kirtan Vyas
 
Lecture 11 Prenatal diagnosis
Lecture 11 Prenatal diagnosisLecture 11 Prenatal diagnosis
Lecture 11 Prenatal diagnosis
Public Health & Medical Academy
 
Preventing preterm labour
Preventing preterm labourPreventing preterm labour
Preventing preterm labour
limgengyan
 
Preventing preterm labour
Preventing preterm labourPreventing preterm labour
Preventing preterm labour
limgengyan
 
Preterm labor by audace
Preterm labor by audacePreterm labor by audace
Preterm labor by audace
Audace L'audacieux
 
TB and IVF results - Fertivision.pptx
TB and IVF results - Fertivision.pptxTB and IVF results - Fertivision.pptx
TB and IVF results - Fertivision.pptx
Jindal IVF Chandigarh
 
Preterm Labour and Premature Rupture of Membranes Mob: 7289915430, www.drprad...
Preterm Labour and Premature Rupture of Membranes Mob: 7289915430, www.drprad...Preterm Labour and Premature Rupture of Membranes Mob: 7289915430, www.drprad...
Preterm Labour and Premature Rupture of Membranes Mob: 7289915430, www.drprad...
Pradeep Garg
 
Recurrent miscarriage ppt gynae seminar
Recurrent miscarriage ppt gynae seminarRecurrent miscarriage ppt gynae seminar
Recurrent miscarriage ppt gynae seminar
obsgynhsnz
 
Interesting Update on Recurrent Miscarriage for Indian Gynaecologoists D...
Interesting Update on  Recurrent  Miscarriage  for Indian Gynaecologoists   D...Interesting Update on  Recurrent  Miscarriage  for Indian Gynaecologoists   D...
Interesting Update on Recurrent Miscarriage for Indian Gynaecologoists D...
Lifecare Centre
 
Gerard visser
Gerard visserGerard visser
Gerard visser
www.tipfakultesi. org
 
Kuwait Newborn Screening Annual report 2015
Kuwait Newborn Screening Annual report  2015Kuwait Newborn Screening Annual report  2015
Kuwait Newborn Screening Annual report 2015
Newborn Screening KW
 
Preterm birth role of hyroxyprogesterone
Preterm birth   role of hyroxyprogesteronePreterm birth   role of hyroxyprogesterone
Preterm birth role of hyroxyprogesterone
Dr. Sunita Chandra
 
The fetus at risk
The fetus at riskThe fetus at risk
The fetus at risk
MiniSood2
 

Similar to Selective embryo-fetal reduction (20)

AN ANALYSIS OF OUTCOMES IN TWIN PREGNANCIES WITH ACTIVE FETAL SURVEILLANCE AN...
AN ANALYSIS OF OUTCOMES IN TWIN PREGNANCIES WITH ACTIVE FETAL SURVEILLANCE AN...AN ANALYSIS OF OUTCOMES IN TWIN PREGNANCIES WITH ACTIVE FETAL SURVEILLANCE AN...
AN ANALYSIS OF OUTCOMES IN TWIN PREGNANCIES WITH ACTIVE FETAL SURVEILLANCE AN...
 
I Jornada Actualización en Genética Reproductiva y Fertilidad
I Jornada Actualización en Genética Reproductiva y Fertilidad I Jornada Actualización en Genética Reproductiva y Fertilidad
I Jornada Actualización en Genética Reproductiva y Fertilidad
 
Preterm Labor by Yinka Oyelese
Preterm Labor by Yinka OyelesePreterm Labor by Yinka Oyelese
Preterm Labor by Yinka Oyelese
 
preterm and postterm labour
 preterm and postterm labour preterm and postterm labour
preterm and postterm labour
 
Unexplained Infertility 2009 (Assisted Reproductive Technologies)
Unexplained Infertility 2009 (Assisted Reproductive Technologies)Unexplained Infertility 2009 (Assisted Reproductive Technologies)
Unexplained Infertility 2009 (Assisted Reproductive Technologies)
 
O&G PRETERM DELIVERY, Tutorial for 2024 v1
O&G PRETERM DELIVERY, Tutorial for 2024 v1O&G PRETERM DELIVERY, Tutorial for 2024 v1
O&G PRETERM DELIVERY, Tutorial for 2024 v1
 
Universal screening for gestational diabetes by DIPSI test by Dr.Preksha
Universal screening for gestational diabetes by DIPSI test by Dr.PrekshaUniversal screening for gestational diabetes by DIPSI test by Dr.Preksha
Universal screening for gestational diabetes by DIPSI test by Dr.Preksha
 
Preterm labor
Preterm laborPreterm labor
Preterm labor
 
Lecture 11 Prenatal diagnosis
Lecture 11 Prenatal diagnosisLecture 11 Prenatal diagnosis
Lecture 11 Prenatal diagnosis
 
Preventing preterm labour
Preventing preterm labourPreventing preterm labour
Preventing preterm labour
 
Preventing preterm labour
Preventing preterm labourPreventing preterm labour
Preventing preterm labour
 
Preterm labor by audace
Preterm labor by audacePreterm labor by audace
Preterm labor by audace
 
TB and IVF results - Fertivision.pptx
TB and IVF results - Fertivision.pptxTB and IVF results - Fertivision.pptx
TB and IVF results - Fertivision.pptx
 
Preterm Labour and Premature Rupture of Membranes Mob: 7289915430, www.drprad...
Preterm Labour and Premature Rupture of Membranes Mob: 7289915430, www.drprad...Preterm Labour and Premature Rupture of Membranes Mob: 7289915430, www.drprad...
Preterm Labour and Premature Rupture of Membranes Mob: 7289915430, www.drprad...
 
Recurrent miscarriage ppt gynae seminar
Recurrent miscarriage ppt gynae seminarRecurrent miscarriage ppt gynae seminar
Recurrent miscarriage ppt gynae seminar
 
Interesting Update on Recurrent Miscarriage for Indian Gynaecologoists D...
Interesting Update on  Recurrent  Miscarriage  for Indian Gynaecologoists   D...Interesting Update on  Recurrent  Miscarriage  for Indian Gynaecologoists   D...
Interesting Update on Recurrent Miscarriage for Indian Gynaecologoists D...
 
Gerard visser
Gerard visserGerard visser
Gerard visser
 
Kuwait Newborn Screening Annual report 2015
Kuwait Newborn Screening Annual report  2015Kuwait Newborn Screening Annual report  2015
Kuwait Newborn Screening Annual report 2015
 
Preterm birth role of hyroxyprogesterone
Preterm birth   role of hyroxyprogesteronePreterm birth   role of hyroxyprogesterone
Preterm birth role of hyroxyprogesterone
 
The fetus at risk
The fetus at riskThe fetus at risk
The fetus at risk
 

Recently uploaded

NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
Dr. Ahana Haroon
 
Outbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptxOutbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptx
Pratik328635
 
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan PatroJune 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
Kanhu Charan
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
Josep Vidal-Alaball
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
LEFLOT Jean-Louis
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
Torstein Dalen-Lorentsen
 
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptxCLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
Government Dental College & Hospital Srinagar
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Holistified Wellness
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
Dr. Nikhilkumar Sakle
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
19various
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
MedicoseAcademics
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
rishi2789
 
pathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathologypathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathology
ZayedKhan38
 
Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
reignlana06
 
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
FFragrant
 
Abortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentationAbortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentation
AksshayaRajanbabu
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
Dr.pavithra Anandan
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
AyeshaZaid1
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
taiba qazi
 

Recently uploaded (20)

NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
 
Outbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptxOutbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptx
 
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan PatroJune 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
 
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptxCLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
 
pathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathologypathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathology
 
Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
 
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
 
Abortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentationAbortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentation
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
 

Selective embryo-fetal reduction

  • 1. The Fetal Medicine Foundation Sofía Fournier Margarita Torrents Cayetana Barbed Mónica Echevarría Mina Comas MARBELLA, JUNE 2013 SELECTIVE EMBRYO-FETAL REDUCTION. OUR EXPERIENCE OVER THE LAST 20 YEARS FACTORS AFFECTING OUTCOME HOSPITAL UNIVERSITARIO QUIRÓN DEXEUS, BARCELONA. SPAIN 0% 10% 20% 30% 40% 50% 60% <37 weeks < 34 weeks < 32 weeks congenital defect multiple pregnancy N: 177 From 1989 to 2011
  • 2. The Fetal Medicine Foundation Selective embryo-fetal reduction. Factors affecting outcome Objective: To analyze our own results in selective embryo-fetal reductions during a 22-year period, focusing on percentage of fetal loss and prematurity rate Material and methods: 177 embryo-fetal reductions performed from 1989 to 2011 149 cases with a complete follow-up (84,2%) Indications: 64,9% multiple pregnancy 35,02% congenital defect Only one operator performing all the cases Introduction: Indications for a selective embryo-fetal reduction in our hospital: -High order multiple pregnancies (>3) or triplets in high-risk patients -Congenital defect in one of the embryos/fetuses
  • 3. The Fetal Medicine Foundation Results: Fetal loss according to: Selective embryo-fetal reduction. Factors affecting outcome P: 0,59 P: 0,77 P: 0,23  No significant relationship with GA.  Higher risk <10th week: linked to cases performed during the initial period (higher number of embryos to reduce and less experience).  Trend higher risk >12th week  No significant relationship with the initial number of fetuses (trend to increased risk when > 3 fetuses)  No significant relationship with the number of fetuses reduced (trend to increased risk when >1 fetus) GA procedure Initial n fetuses n fetuses reduced
  • 4. The Fetal Medicine Foundation Results: Selective embryo-fetal reduction. Factors affecting outcome INDICATION OVERALL CONGENITAL DEFECT MULTIPLE PREGNANCY NOT COMPLETE INFORMATION 13 21% 15 13% 28 15,8% FETAL LOSS 5 8,1% 12 10,4% 17 9,6% < 37 WEEKS 9 14,5% 49 42,6% 58 32,8% >37 WEEKS 35 56,5% 39 33,9% 74 41,8% OVERALL 62 35,02% 115 64,9% 177 100% Overall fetal loss rate: 9,6%  8,1% when congenital defect 10,4% when multiple pregnancy Overall prematurity rate: 32,8% 14,5% in the congenital defect group 42,6% in the multiple pregnancy group P < 0,05 0% 10% 20% 30% 40% 50% 60% multiple pregnancy congenital defect P>0,05 Learning curve % fetal loss
  • 5. The Fetal Medicine Foundation Conclusions Thank you Selective embryo-fetal reduction. Factors affecting outcome 11%  Indication for selective embryo-fetal reduction has significantly changed:  Multiple pregnancies in high-risk patients used to be the most frequent  Congenital defects is the most frequent indication nowadays  The overall perinatal result is worse in cases due to multiple pregnancy, with a higher rate of fetal loss and prematurity.  No significant relationship with GA, initial number of fetuses nor number of fetuses reduced  Trend to increased risk when >12 weeks (importance of earlier diagnosis)  Trend to increased risk when >3 initial fetuses  Trend to increase when >1 fetus reduced Performing the technique by expert hands with an appropriate learning curve guarantees better perinatal results.

Editor's Notes

  1. Hello, my name is Sofia Fournier. I come from Barcelona and I’m going to talk about our series in selecive embryo-fetal reductions. We have been performing this technique since 1989, and I will focus on the factor affecting pregnancy outcome. In our hospital the indications for practising this technique are: when we have a high order multiple pregnancy, which was something quite frequent in the beggining due to initial reproductive assisted techniques, in cases of triplets in high risk patients or in twins with a congenital defect in one of the embryos or fetuses. Usually in the firs case the reduction is performed before than in the case of a congenital defect in one of the twins. The aim of our study is to analyze our own results during a 22 year period, focusing on percentage of fetal loss and prematurity rate. We have performed 177 embryo-fetal reductions in our feto-maternal unit, from 1989 to 2011. We have a complete follow up of 149 cases. And depending on the indication, we have 65% of cases due to multiple pregnancy and 35% due to congenital defect. Only one operator performed all the techniques.
  2. We have a long serie of cases, not only for the number of cases but as well for the long period of time, and that’s been a factor affecting on our possibilities of collecting all the information. Nevertheless we have been able to find out some factors affecting the outcome: the gestational age in which we perform the technique, the initial number of fetuses and the number of fetuses reduced. We did not find a significant relationship with any of those factors, but if we analyze the results in function of the gestational age wue can see that the higher risk in performing the reduction before the 10th week is linked to those cases performed during the initial period, when there were more embryos to reduce and less experience. And excluding that fact we can see a trend in having more risk when performing it after the 12th week. In the case of the initial number of fetuses, we also can see an increase of risk when it is more than 3 embryos. And finally if we take into account the number of fetus reduced, we also see a trend to an increased risk when we reduce more than one fetus.
  3. When we analyze the results depending on the main indication we can see that the fetal loss rate is very similar in both groups but not the overall prematurity rate, which is significantly higher in the multiple pregnancy group, as expected. The numbers of overall prematurity are in the case of multiple pregnancy very similar to our multiple pregnancies that haven’t undergone a reduction, but when we take a look at prematurity before 34 or 32 weeks is quite higher in the reduced group that in normal twin pregnancies (15% and 7% in reduced pregnancies and 6% and 5% in the normal ones). If we compare the pregnancies that have undergone a reduction of a fetus with a congenital defect and then continue to be singletone pregnancies, the rate of prematurity is higher than our rate of prematurity in singletons, that is around 5%. And finally, taking advantage of the fact that all the reductions in our hospital have been performed mainly by one operator we have analyzed the effect that the learning curve can have in the outcome. Although the results have no statistical significance, we have found a reduction in the percentage of fetal loss from the beggining till nowadays.
  4. And just to conclude, i would like to say that the indication for selective embryofetal reduction in our hospital has clearly changed with the years, being multiple pregnancies the main reason in the beggining and congenital defects in twin pregnancies the most frequent indication nowadays. The overall perinatal result is worse in cases due to multiple pregnancy, as expected, with a higher rate of fetal loss and prematurity. That even if there is no significant relationship with the gestational age in which performing the technique, the initial number of fetuses nor the number of fetuses reduced, we have found a trend to increased risk if performing the technique after the 12th week of pregnancy ( so that’s why first trimestre diagnosis), if the initial number of fetuses is higher than 3 or if we have to reduce more than one fetus. Finally, we can conclude that performing those reductions by expert hands with a good learning curve, the final results will be better. Thank you very much.